Last 14 quarters of trend data · Healthcare · Immunology Biotech
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q2 '26 | Q4 '25 | Q2 '25 | Q4 '24 | Q2 '24 | Q4 '23 | Q2 '23 | Q4 '22 | Q2 '22 | Q4 '21 | Q2 '21 | Q4 '20 | Q4 '19 | Q2 '19 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -0.73 | — | — | — | — | 2.71 | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 716.90 | 12.74 | — | 283.27 | 27.28 | 0.88 | — | — | — | — | — | — | — | — | — |
| — | +1355.3% | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/B Ratio | 0.97 | 5.57 | 3.74 | 0.76 | 0.83 | 0.76 | 0.64 | 3.52 | 2.08 | 1.50 | 6.47 | 18.40 | — | — | — |
| — | +629.0% | +484.0% | -78.3% | -60.2% | -49.2% | -90.1% | -80.9% | — | — | — | — | — | — | — | |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | -0.45 | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | — | -0.43 | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q2 '26 | Q4 '25 | Q2 '25 | Q4 '24 | Q2 '24 | Q4 '23 | Q2 '23 | Q4 '22 | Q2 '22 | Q4 '21 | Q2 '21 | Q4 '20 | Q4 '19 | Q2 '19 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 100.0% | 100.0% | — | 100.0% | 100.0% | 100.0% | — | — | — | — | — | — | — | — | — |
| — | 0.0% | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Operating Margin | -90740.6% | -1267.0% | — | -27966.7% | -1378.1% | 56.6% | — | — | — | — | — | — | — | — | — |
| — | -2339.1% | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Net Margin | -86687.5% | -1249.0% | — | -26872.9% | -1275.9% | 61.6% | — | — | — | — | — | — | — | — | — |
| — | -2128.7% | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | Q2 '26 | Q4 '25 | Q2 '25 | Q4 '24 | Q2 '24 | Q4 '23 | Q2 '23 | Q4 '22 | Q2 '22 | Q4 '21 | Q2 '21 | Q4 '20 | Q4 '19 | Q2 '19 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -82.7% | -106.6% | -26.7% | -15.8% | -8.8% | 14.0% | -53.1% | -150.3% | -206.7% | -160.6% | -122.4% | -1130.5% | — | — | — |
| — | -860.8% | +49.8% | +89.5% | +95.7% | +108.7% | +56.6% | +86.7% | — | — | — | — | — | — | — | |
| ROA | -70.5% | -73.7% | -21.8% | -14.0% | -8.0% | 12.0% | -43.0% | -135.2% | -187.4% | -148.3% | -116.0% | -376.4% | -0.3% | -20.8% | -19.5% |
| — | -715.4% | +49.3% | +89.6% | +95.7% | +108.1% | +62.9% | +64.1% | -68980.9% | -614.4% | -495.5% | — | — | — | — | |
| ROIC | -472.5% | -1170.9% | -64.9% | -44.1% | -97.9% | 1624.5% | -1944.3% | -289.1% | -364.9% | -780.8% | -4091.3% | — | — | — | — |
| — | -172.1% | +96.7% | +84.8% | +73.2% | +308.0% | +52.5% | — | — | — | — | — | — | — | — |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q2 '26 | Q4 '25 | Q2 '25 | Q4 '24 | Q2 '24 | Q4 '23 | Q2 '23 | Q4 '22 | Q2 '22 | Q4 '21 | Q2 '21 | Q4 '20 | Q4 '19 | Q2 '19 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.02 | 0.02 | 0.02 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
| — | +654.2% | +258.8% | +164.0% | -29.4% | +11.7% | +898.0% | +776.5% | — | — | — | — | — | — | — | |
| Debt / EBITDA | — | — | — | — | — | 0.02 | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 3.74 | 2.37 | 3.74 | 7.24 | 11.46 | 12.04 | 4.85 | 9.26 | 9.97 | 9.58 | 15.30 | 23.15 | 27.81 | 13.24 | 24.43 |
| — | -80.3% | -22.8% | -21.8% | +14.9% | +25.7% | -68.3% | -60.0% | -64.2% | -27.7% | -37.4% | — | — | — | — | |
| Quick Ratio | 3.74 | 2.37 | 3.74 | 7.24 | 11.46 | 12.04 | 4.85 | 9.26 | 9.97 | 9.58 | 15.30 | 23.15 | 27.81 | 12.44 | 23.79 |
| — | -80.3% | -22.8% | -21.8% | +14.9% | +25.7% | -68.3% | -60.0% | -64.2% | -23.0% | -35.7% | — | — | — | — | |
| Interest Coverage | — | — | — | — | — | 744.85 | -3435.41 | -2936.66 | -4585.92 | -7038.96 | — | — | — | -3172.79 | -3172.79 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 14 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying CNTB stock.
Connect Biopharma Holdings Limited's current P/E is -0.7x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Connect Biopharma Holdings Limited's current operating margin is -90740.6%. Margins have been expanding over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Connect Biopharma Holdings Limited's business trajectory between earnings reports.